Kura Oncology Inc. (KURA) Receives Outperform Rating from Leerink Swann
Several other research analysts have also recently weighed in on KURA. Oppenheimer Holdings Inc. restated an outperform rating and set a $16.00 target price on shares of Kura Oncology in a report on Tuesday, June 21st. Zacks Investment Research upgraded Kura Oncology from a hold rating to a buy rating and set a $3.75 target price on the stock in a report on Wednesday, July 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $14.15.
Shares of Kura Oncology (NASDAQ:KURA) traded down 0.35% during midday trading on Thursday, hitting $5.74. The stock had a trading volume of 3,270 shares. The firm’s market cap is $107.58 million. Kura Oncology has a 52-week low of $2.50 and a 52-week high of $25.00. The firm’s 50 day moving average price is $6.15 and its 200 day moving average price is $4.19.
Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. On average, equities research analysts expect that Kura Oncology will post ($1.58) earnings per share for the current year.
An institutional investor recently bought a new position in Kura Oncology stock. Alethea Capital Management LLC acquired a new position in Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned approximately 0.34% of Kura Oncology as of its most recent SEC filing. Institutional investors and hedge funds own 43.63% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.